Literature DB >> 1139862

Effects of oral propranolol in normal subjects.

M M LeWinter, M H Crawford, J S Karliner, R A ORourke.   

Abstract

The effects of oral propranolol were evaluated in 10 normal volunteers. The resting heart rate decreased from the mean control value of 68 plus or minus 3.3 (SE) to 56 plus or minus 2.8 beats per minute (bpm) on propranolol (p smaller than 0.001, paired test). Mean systolic blood pressur also decreased from 125 plus or minus 5.0 to 114 plus or minus 4.2 mm Hg (p smaller than 0.03). Resting systolic time intervals were unaffected by propranolol. Mean maximal treadmill exercise tolerance time was not significantly altered by propranolol although the mean heart rate systolic blood pressure product a maximal exertion was markedly decreased (1.91 plus or minus 0.17 vs 2.62 plus or minus 0.17 times 10-4, p smaller than 0.004) . The nonsignificant effect of oral propranolol on resting systolic time intervals and maximum exercise tolerance despite significant changes in heart rate and blood pressure at rest and duringexercise stand in contrast to the reported effects of intravenous propranolol. Explantations for this difference between the effects of oral and intravenous propranolol in normal subjects are examined.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1139862     DOI: 10.1002/cpt1975176709

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  Blockade of cardiac and renal beta-receptors by low dose propranolol in normal subjects. Clues to its antihypertensive effect.

Authors:  R Davies; T G Pickering; A Morganti; M Wilson; J H Laragh
Journal:  Br Heart J       Date:  1979-03

2.  Maximal aerobic power and blood pressure in normotensive subjects after acute and chronic administration of metoprolol.

Authors:  M van Baak; W Jennen; F T Verstappen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Dissociation between duration of plasma catecholamine and blood pressure responses to beta-adrenergic blockade in normotensive subjects during physical exercise.

Authors:  G Planz; R Planz
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

Review 4.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

5.  Left ventricular function and beta-blockers: does intrinsic sympathomimetic activity have any influence during chronic therapy?

Authors:  R J Northcote; M B Cooke; D Ballantyne
Journal:  Cardiovasc Drugs Ther       Date:  1988-11       Impact factor: 3.727

Review 6.  Exercise performance and beta-blockade.

Authors:  P A Tesch
Journal:  Sports Med       Date:  1985 Nov-Dec       Impact factor: 11.136

7.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

8.  Atenolol reduces blood pressure and FEV in normal subjects.

Authors:  R W Fuller; P J Vallance
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

9.  Propranolol and the respiratory, circulatory, and ECG responses to high altitude.

Authors:  U Boutellier; E A Koller
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1981

10.  Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol.

Authors:  Max Tsai; Michael Case; Paul Ardayfio; Helen Hochstetler; Darren Wilbraham
Journal:  Clin Pharmacol Drug Dev       Date:  2020-01-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.